We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.


New Trading Tool: Live US Options Flow! Try it out.

RENX Renalytix Plc

2.50 (3.03%)
22 Sep 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.

Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.50 3.03% 85.00 80.00 90.00 85.00 82.50 82.50 32,308 08:18:44
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Services, Nec 3.0 -56.7 -75.9 - 80.61

Renalytix PLC Expansion of insurance coverage for KidneyIntelX (1093A)

22/05/2023 7:00am

UK Regulatory (RNS & others)

Renalytix (LSE:RENX)
Historical Stock Chart

From Mar 2023 to Sep 2023

Click Here for more Renalytix Charts.


RNS Number : 1093A

Renalytix PLC

22 May 2023

Renalytix plc

("Renalytix" or the "Company")

Expansion of insurance coverage for KidneyIntelX(TM)

LONDON and SALT LAKE CITY, May 22, 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX) reports the expansion of insurance coverage for KidneyIntelX with CareFirst BlueCross BlueShield, the largest health care plan in the Mid-Atlantic region of the United States. In total, CareFirst BlueCross BlueShield serves 3.4 million members in Maryland, DC, and Northern Virginia, as well as the Federal Employee Program (FEP), also known as the Blue Cross and Blue Shield Service Benefit Plan which is part of the Federal Employees Health Benefits (FEHB) Program administered by CareFirst. This agreement complements coverage already secured with Wellmark Blue Cross Blue Shield in Iowa and South Dakota (estimated 2.1 million covered lives) and BlueCross BlueShield of Illinois (estimated 8.1 million covered lives).

For further information, please contact:

Renalytix plc                                                                               www.renalytix.com 
James McCullough, CEO                                                                         Via Walbrook PR 
Stifel (Nominated Adviser, Joint Broker)                                                   Tel: 020 7710 7600 
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea 
Investec Bank plc (Joint Broker)                                                           Tel: 020 7597 4000 
Gary Clarence / Shalin Bhamra 
Walbrook PR Limited                                            Tel: 020 7933 8780 or renalytix@walbrookpr.com 
Paul McManus / Lianne Applegarth                                           Mob: 07980 541 893 / 07584 391 303 
CapComm Partners 
Peter DeNardo                                                    Tel: 415-389-6400 or investors@renalytix.com 

About Kidney Disease

Kidney disease is a public health epidemic affecting over 850 million people globally.(1) The Centers for Disease Control and Prevention estimates that 15% of U.S. adults, or over 37 million people(2) , have chronic kidney disease (CKD). Nearly 95% of people with CKD are in early stages 1-3(3) . Despite its magnitude, early-stage (1-3) CKD is underdiagnosed and undertreated, largely because it's asymptomatic at this time in the disease. As many as 9 in 10 adults with CKD, and 2 in 5 adults with severe CKD do not know they have the condition.(3)

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis(TM) for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

About KidneyIntelX(TM)

KidneyIntelX(TM) is a laboratory developed test demonstrated to be a reliable, bioprognostic(TM) methodology that yields a simple-to-understand, custom risk score, enabling prediction of which adult patients with T2D and early CKD (stages 1-3) are at low, intermediate or high risk for rapid progressive decline in kidney function. By combining information from KidneyIntelX with newer cardio- and reno-protective therapies, doctors will have more information in determining which patients are at higher versus lower risk for rapid disease progression and may be able to more appropriately target resources and guideline-recommended treatments to advance kidney health. KidneyIntelX is supported by a growing body of clinical, utility and health economic studies (including a validation study of two large cohorts) and has a demonstrated a 72% improvement in predicting those patients who are at high risk for rapid progressive decline in kidney function versus the current standard of care (eGFR and UACR). KidneyIntelX has received Breakthrough Device Designation from the U.S. Food and Drug Administration and Renalytix has submitted for De Novo marketing authorization. To learn more about KidneyIntelX and review the evidence, visit www.kidneyintelx.com.



2 https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html

3 https://www.cdc.gov/kidneydisease/basics.html

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential benefits of KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects of KidneyIntelX, if approved, including whether and to what extent KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery, mitigate patient overload in nephrology, address systemic inequalities and improve patient outcomes. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section of our annual report on Form 20-F filed with the SEC on October 31, 2022, and other filings we make with the SEC from time to time. All information in this press release is as of the date of the release, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

May 22, 2023 02:00 ET (06:00 GMT)

1 Year Renalytix Chart

1 Year Renalytix Chart

1 Month Renalytix Chart

1 Month Renalytix Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: gb D: 20230924 05:16:20